temozolomide / Generic mfg. - LARVOL DELTA

α-Conopeptide From Conus planorbis Inhibits Glioblastoma Stem Cells and Angiogenesis via Sonic Hedgehog and ADAMDEC1-FGF2-FGFR1 Loop Signaling Pathway. (PubMed, Chem Biodivers) - "Additional chorioallantoic membrane (CAM) and brine shrimp lethality tests supported its potent bioactivity, with a lower LD50 (50.24 µg/mL) compared to temozolomide (125.82 µg/mL). These findings indicate that the α-conopeptide from C. planorbis possesses multi-target anticancer activity targeting via SHH and FGFR1 loop signaling pathway, structural stability, and superior cytotoxic potency against GBM, highlighting its potential as a novel marine-derived therapeutic agent."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • FGF2 • FGFR1 • PTCH1

Personalized chronotherapy in glioblastoma: integrating circadian profiling and PK-PD modelling to optimize temozolomide timing. (PubMed, NPJ Precis Oncol) - "A mechanistic pharmacokinetic-pharmacodynamic model incorporating the clock network recapitulated experimental observations and enabled prediction of treatment timing. Our findings highlight the importance of timing in GBM therapy and propose combining circadian profiling with mathematical modeling to personalize GBM chronotherapy."

Journal • PK/PD data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ARNTL • BMAL1 • CLOCK • NR1D1 • PER2

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Bryan Allen | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting (ASH 2025) - "During induction, 59% received HDMTX+rituximab (R), 39% received HDMTX+R+additional (A) chemotherapy such as temozolomide (MTR) (15%) and cytarabine/thiotepa (MATRix) (15%)...Thiotepa (TT)/BCNU was used for conditioning in 8 patients, and TT/Busulfan/Cyclophosphamide in 1... HDMTX-based induction chemotherapy is effective in patients with PCNSL, even in those with delayed diagnosis or initiation of therapy. Although a minority of patients received consolidation with ASCT, it was associated with 100% progression-free survival."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Pulmonary Disease • Respiratory Diseases • Transplantation

Efficacy and safety of bmetl regimen (Orelabrutinib plus Semustine, Temozolomide and Lenalidomide) with subsequent maintenance treatment in elderly/frail patients with CNSL (ASH 2025) - "After induction therapy, patients with objective response received sequential MT regimen (methotrexate 3 mg/m 2 , day 1; thiotepa 20 mg/m 2 , day 2) in a 21-day cycle for 2-4 cycles... BMeTL regimen with subsequent maintenance treatment is effective and well-tolerated for elderly/frail patients with CNSL. This study provides a potential novel strategy for this elderly/frail population."

Clinical • Agranulocytosis • CNS Lymphoma • Geriatric Disorders • Granulocytopenia • Hematological Malignancies • Infectious Disease • Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. (PubMed, J Clin Oncol) - "Within a randomized phase II setting, results observed with addition of dB to T-based chemotherapy in RR-HR-NB warrant further evaluation."

Journal • P2 data • Neuroblastoma • Oncology • Solid Tumor

VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study. (PubMed, Discov Oncol) - P2 | "VAL-083 (30 mg/m2/day) combined with radiation therapy was generally safe and well tolerated. Adverse events aligned with previous studies. This regimen, compared to standard-of-care TMZ, showed potential benefits in terms of disease progression and overall survival. Trial registration ClinicalTrials.gov ID NCT03050736, dated: February 13, 2017."

Journal • P2 data • Brain Cancer • Glioblastoma • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • MGMT

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis (ASH 2025) - "First-line treatments were mainly HD-MTX alone (38%),HD-MTX + temozolomide (17%), or vincristine + procarbazine (12%)...Twelve patients (29%) underwent consolidative autologoustransplant, most commonly with thiotepa/carmustine (TT/BCNU, 69%) or BEAM conditioning (25%).Median duration of follow-up was 10.4 months... Forty-two pts met inclusion criteria. Median age was 57 (range 19–77), 69% were male, and 79%were white. Most (69%) had ECOG 0–1."

Retrospective data • CNS Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Organ Transplantation • T Cell Non-Hodgkin Lymphoma • ALK • DNMT3A • TP53

Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways (ASH 2025) - "To assess HSC transplantation efficacy, mice were conditioned with 700 or1000 Rads of TBI, transplanted with 2 million CD45.1 bone marrow (BM) cells, and monitored for donorcell engraftment for 4 months. Quizartinib synergized with DNA damaging chemotherapeutic agents (cyclophosphamide,carboplatin, cisplatin, temozolomide, and mitoxantrone) to deplete HSPC populations. Quizartinib sensitizes HSPCs to DNA-damaging therapies via downregulation of DNA repairgenes and impaired resolution of DNA damage, resulting in enhanced HSPC depletion. This quizartinib-driven sensitization demonstrated improved engraftment after HSCT in murine models. These resultsprovide a rationale for incorporating quizartinib into reduced-intensity, myeloablative conditioningregimens to improve transplant outcomes while minimizing non-hematopoietic toxicity."

Bone Marrow Transplantation • Transplantation • BRCA1 • BRCA2 • CD34 • FLT3 • NBN • PTPRC • RAD51

Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma (ASH 2025) - P2, P3 | "No approved therapies for relapsedor refractory (r/r) disease exist in the US or EU, and NCCN guideline-recommended treatment optionsbased on small studies can be divided into high-dose chemotherapy (HDC) with or without autologousstem cell transplantation (ASCT), whole brain radiation therapy (WBRT), or treatment with better-tolerated regimens such as temozolomide (TMZ) or lenalidomide with or without rituximab (RTX), RTX,pomalidomide, ibrutinib, or pemetrexed...Tumor response assessment will be performed at screening, C2D1, C3D1, thenevery 2 cycles through C25D1, and every 4 cycles thereafter according to IPCG criteria. ClinicalTrials.govregistration number: NCT07104032."

Clinical • P3 data • CNS Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Pruritus

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients (ASH 2025) - "Induction regimens included 1) HD-MTX, temozolomide, and rituximab (MTR, 36%); 2) HD-MTX, procarbazine, and vincristine (MPV/variants, 33%); 3) HD-MTX, rituximab (25%); 4) HD-MTXalone/other (4%)...Cons regimens includedcytarabine (43%), etoposide+cytarabine (25%), radiation (22%), cytarabine+X (8%) and others (2%). Maintincluded rituximab-based therapy (26%), HD-MTX (22%), temozolomide (18%), BTK inhibitors (BTKi) (16%),HD-MTX+BTKi (3%), lenalidomide (14%) and other (3%)...Despite heterogeneous post-induction approaches, outcomes were similar across strategies, andinstitutional preference largely determined treatment choice, highlighting the absence of standardizedcare pathways. Given comparable efficacy, lower-intensity, less toxic regimens may be appropriate forthis vulnerable population."

Clinical • Alzheimer's Disease • CNS Lymphoma • Cognitive Disorders • Dementia • Depression • Epilepsy • Febrile Neutropenia • Geriatric Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Osteoporosis • Primary Central Nervous System Lymphoma • Psychiatry • Rheumatology • Transplantation

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies (ASH 2025) - "Patients deemed adequately fit were assigned to receive the standard combination of HDMTX,procarbazine, and rituximab as induction therapy...Patients ineligible for HDMTX wereassigned to receive concomitant whole-brain radiotherapy, temozolomide, and rituximab as inductiontherapy, followed by maintenance temozolomide (Part B)...The 3-year OS was 44 (±16%) forprocarbazine and 54 (±14%) for lenalidomide... Risk of treatment failure (in terms of dropout and survival rates) appeared higher comparedto the PRIMAIN trial. Discrepancies in feasibility and efficacy between PRIMAIN and FIORELLA trialsgenerate some concerns about generalization of results of PCNSL trials among different geographicalregions.These unexpected outcomes offer several valuable lessons on the incorporation of comorbidity indexesinto trial eligibility/stratification and the relevance of interim analyses to inform ethical decisions early."

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Subarachnoid Hemorrhage

Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC) (ASH 2025) - "52% received high dose MTX, rituximab, and temozolomide... We identified highly recurrent genetic alterations in PCNSL, with MYD88, TP53, and IRF4 mutationsobserved less frequently in Hispanic patients. These findings support ethnic variability in the molecularlandscape of PCNSL. Despite these genetic differences, Hispanic patients had comparable 2-year PFS andOS."

Clinical • Clinical data • CNS Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • CARD11 • CD79B • CDKN2A • DNMT3A • ETV6 • IRF4 • KMT2D • MYD88 • PIM1 • PRDM1 • TET2 • TP53

Improving outcomes with nivolumab consolidation among older patients (≥65) with previously untreated primary CNS lymphoma (ASH 2025) - P1 | "Induction chemotherapy regimens included 36% R-MPV (rituximab, methotrexate,procarbazine, and vincristine), 21% MRT (methotrexate, rituximab, and temozolomide), 21% MR(methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab).Following induction chemotherapy, 64% achieved a complete response (CR), 29% achieved a partialresponse (PR), and 7% had a stable disease (SD)... This study demonstrates favorable safety and clinical outcomes with nivolumab consolidationin older PCNSL patients unsuitable for ASCT or WBRT. No DLTs were observed during the safety run-inphase, and there were no unexpected toxicities associated with nivolumab, although one earlydiscontinuation occurred due to Stevens-Johnson syndrome, a rare but known AE of nivolumab. Overall,the absence of DLTs and encouraging survival outcomes support further investigation."

Clinical • IO biomarker • Alzheimer's Disease • CNS Lymphoma • Cognitive Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome

MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy (ASH 2025) - "While MGMT is a predictivebiomarker for temozolomide (TMZ) in glioma, its role in AML remains underexplored, despite evidence ofMGMT silencing in subsets of AML.We conducted a multi-omics analysis of 34 de novo and 15 relapsed/refractory AML samples from theYale Hematology Tissue biobank, alongside MGMT methylation and expression analysis in 170 TCGA AMLcases...We are now screening the MGMT-deficient AML samples forMMR protein expression. Identification of MMR deficiency as a key resistance mechanism to TMZ in thesepatients could further explain its poor efficacy observed in previous AML trials.This comprehensive study explains the limited potential of TMZ in MGMT-silenced AML and provides therationale to initiate clinical trials with a novel time-dependent crosslinker (KL50) in a biomarker drivenfashion in AML."

Biomarker • IO biomarker • Acute Myelogenous Leukemia • Brain Cancer • Glioma • Hematological Malignancies • Leukemia • Solid Tumor • CD34 • FLT3 • GLI2 • IDH1 • IDH2 • IL2RG • MGMT • MSH6 • PTPRC • SIRPA

Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Feb 2026 ➔ Feb 2028 | Trial primary completion date: Feb 2026 ➔ Feb 2028

Trial completion date • Trial primary completion date • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor

Retrospective single-center study comparing the effectiveness of sunitinib and chemotherapy based on alkylating agents in the treatment of metastatic pheochromocytomas/paragangliomas (ESMO Asia 2025) - "Comparative data on the effectiveness of these options are lacking, which is the purpose of this study. This retrospective single-center study included patients (pts) over 18 years of age who received alkylating agents-based ChT (dacarbazine or temozolomide) or sunitinib (SUN) +/- somatostatin analogues (SA) for metastatic PC/PG from September 2015 to January 2025. The study included 46 pts, 23 in each group. Sunitinib and chemotherapy based on alkylating agents demonstrate comparable efficacy in the treatment of metastatic PC/PG. The choice of therapy should be based on the safety profile of the drug."

Metastases • Retrospective data • Endocrine Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor • SDHB

Role of FAPI [Fibroblast Activation Protein Inhibitor]- PET CT imaging for radiotherapy planning in glioblastoma cases: A pilot study (ESMO Asia 2025) - "RT target volumes were delineated as per standard contouring guidelines taking into account information from both modalities and RT was delivered by IMRT with concurrent and adjuvant temozolomide... FAPI shows good correlation with MRI in delineation of tumor volume in glioblastoma. More accurate, potentially smaller target can result in better sparing of normal tissues. FAPI PET can be a useful tool for RT treatment planning and response assessment in glioblastoma."

Clinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

RBM7 suppresses mitochondrial dysfunction and ferroptosis by destabilizing FBXL16 mRNA to enhance Temozolomide resistance in glioblastoma. (PubMed, Mol Genet Genomics) - "An actinomycin D assay analyzed FBXL16 mRNA stability. RBM7 promotes TMZ resistance by suppressing mitochondrial dysfunction and ferroptosis through destabilization of FBXL16. Targeting the RBM7-FBXL16 axis may represent a novel strategy to overcome GBM chemoresistance."

Journal • Brain Cancer • Glioblastoma • Metabolic Disorders • Oncology • Solid Tumor • ATF4 • FBXL16 • TCF4

Treatment strategies and innovation for recurrent high-grade glioma. (PubMed, J Neurooncol) - "Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care."

IO biomarker • Journal • Review • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor • BRAF • NTRK

Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China. (PubMed, Eur J Med Res) - "The ORT-M/A chemotherapy regimen was efficacious and well-tolerated in our patients with PCNSL. This retrospective study provided a potential therapeutic strategy for PCNSL patients who are unfit for intensive chemotherapy and warrant further investigation."

Journal • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Thrombocytopenia

Pretargeted Polymeric Systems for Conducting Chemo-Radiotherapy on Glioblastoma: An Evaluation of the Impact of Nanomedicine Structure on Bioorthogonal Chemistry In Vivo. (PubMed, Biomacromolecules) - "This study developed a nanoscaled system combining chemotherapeutic (Temozolomide, TMZ) and radionuclide (177Lu) for targeted glioblastoma (GBM) treatment...This then led to a more efficient click reaction in vivo and higher 177Lu accumulation in the tumor. This study provides key information on design considerations for optimal positioning of bioorthogonal reactive species in nanomedicine and a potential treatment approach for GBM."

Journal • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Efficacy of capecitabine and temozolomide (CAPTEM) in patients with gastrointestinal neuroendocrine tumors (GI-NETs). (ASCO-GI 2026) - "The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Gastrointestinal Cancer • Oncology • Solid Tumor

Expression and Functional Role of the P2X7 Receptor in Glioma Models and Tissues: A Systematic Review. (PubMed, Cancers (Basel)) - "Despite a multimodal therapeutic approach combining surgery, radiotherapy, and temozolomide (TMZ), treatment remains highly challenging, and the prognosis is poor...Due to the heterogeneity of models and endpoints, a narrative synthesis was performed. Overall, current evidence suggests that P2X7R may represent a biologically relevant and pharmacologically actionable target in gliomas, although further high-quality studies are required to confirm its clinical potential."

Journal • Review • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Targeting Unc5b induces blood-brain barrier permeability and improves chemotherapy delivery and efficacy in glioblastoma (SNO 2025) - "Importantly, we demonstrated for the first time that anti-Unc5B-induced BBB opening enhances delivery of both conventional chemotherapies, such as doxorubicin and temozolomide, and targeted therapies, including the EGFRvIII-specific inhibitor osimertinib, in GBM-bearing mice. This enhanced delivery resulted in reduced tumor burden, increased tumor cell apoptosis, and improved survival. These findings represent the first preclinical validation of anti-Unc5B monoclonal blocking antibody in glioblastoma models and highlight its potential to improve drug delivery and therapeutic efficacy in brain tumors."

Clinical • Brain Cancer • Glioblastoma • Solid Tumor • Targeted Protein Degradation • CLDN5